Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 3/2016

Open Access 01-03-2016 | Review Article

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Authors: Prajakta S. Badri, Jennifer R. King, Akshanth R. Polepally, Barbara H. McGovern, Sandeep Dutta, Rajeev M. Menon

Published in: Clinical Pharmacokinetics | Issue 3/2016

Login to get access

Abstract

The development of direct-acting antiviral (DAA) agents has reinvigorated the treatment of hepatitis C virus infection. The availability of multiple DAA agents and drug combinations has enabled the transition to interferon-free therapy that is applicable to a broad range of patients. However, these DAA combinations are not without drug–drug interactions (DDIs). As every possible DDI permutation cannot be evaluated in a clinical study, guidance is needed for healthcare providers to avoid or minimize drug interaction risk. In this review, we evaluated the DDI potential of the novel three-DAA combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir (the 3D regimen) with more than 200 drugs representing 19 therapeutic drug classes. Outcomes of these DDI studies were compared with the metabolism and elimination routes of prospective concomitant medications to develop mechanism-based and drug-specific guidance on interaction potential. This analysis revealed that the 3D regimen is compatible with many of the drugs that are commonly prescribed to patients with hepatitis C virus infection. Where interaction is possible, risk can be mitigated by paying careful attention to concomitant medications, adjusting drug dosage as needed, and monitoring patient response and/or clinical parameters.
Literature
1.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.PubMedCentralCrossRefPubMed
2.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.CrossRefPubMed
3.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed
4.
Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(430–41):e6.PubMed
5.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed
6.
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–82.CrossRefPubMed
7.
Menon RM, Klein CE, Lawal AA, Chiu Y-L, Awni WM, Podsadecki TJ, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. HepDART 2009. Kohala Coast; 2009.
8.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(359–65):e1.PubMed
9.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed
10.
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefPubMed
11.
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.CrossRefPubMed
12.
Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. North Chicago: AbbVie Inc.; 2014.
13.
Lin C-W, Menon R, Liu W, Mensing S, Podsadecki T, Shulman N, et al. Exposure-safety response relationship for paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin in hepatitis C genotype 1 virus-infected subjects in phase III studies. In: American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting. New Orleans; 2015.
14.
Khatri A, Dutta S, Marbury T, Preston RA, Rodrigues L, Jr., Wang H, et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r. ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. In: AASLD/EASL Special Conference on Hepatitis C. New York; 2014.
15.
Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.CrossRefPubMed
16.
Ravi S, Nasiri-Toosi M, Karimzadeh I, Khalili H, Ahadi-Barzoki M, Dashti-Khavidaki S. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opin Drug Saf. 2014;13:277–86.CrossRefPubMed
17.
Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012;12:86.PubMedCentralCrossRefPubMed
18.
Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.PubMedCentralCrossRefPubMed
19.
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014;58:4555–64.PubMedCentralCrossRefPubMed
20.
Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013;38:1365–72.CrossRefPubMed
21.
Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;26:1073–82.PubMedCentralCrossRefPubMed
22.
23.
24.
Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C Virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir. In: AASLD/EASL Special Conference on Hepatitis C. New York; 2014.
25.
26.
Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, et al. Drug-drug interactions of commonly used medications with direct acting antiviral HCV combination therapy of paritaprevir/r, ombitasvir and dasabuvir. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC; 2015.
27.
van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159–68.CrossRefPubMed
28.
Burger DM, Huisman A, Van Ewijk N, Neisingh H, Van Uden P, Rongen GA, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84:698–703.CrossRefPubMed
29.
Khatri A, Wang T, Wang H, Podsadecki TJ, Trinh RN, Awni WM, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2014.
30.
Celebrex (celecoxib) capsules [prescribing information]. New York: GD Searle LLC; 2011.
31.
King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci. 2001;61:49–53.CrossRefPubMed
32.
Kaji H, Kume T. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetic acid (TA-1801A). Drug Metab Pharmacokinet. 2005;20:212–8.CrossRefPubMed
33.
Crespi CL, Chang TK, Waxman DJ. Determination of CYP2C9-catalyzed diclofenac 4′-hydroxylation by high-performance liquid chromatography. Methods Mol Biol. 2006;320:109–13.PubMed
34.
Tougou K, Gotou H, Ohno Y, Nakamura A. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004;34:449–61.CrossRefPubMed
35.
Patel M, Tang BK, Kalow W. (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics. 1995;5:43–9.CrossRefPubMed
36.
Ansaid (flurbiprofen) tablets [prescribing information]. New York: Pharmacia & Upjohn Company; 2010.
37.
Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005;33:1027–35.CrossRefPubMed
38.
Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(−)-Ibuprofen. Antimicrob Agents Chemother. 2006;50:1967–72.PubMedCentralCrossRefPubMed
39.
Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos. 1998;26:261–6.PubMed
40.
Sabolovic N, Magdalou J, Netter P, Abid A. Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life Sci. 2000;67:185–96.CrossRefPubMed
41.
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52:293–8.CrossRefPubMed
42.
Feldene (piroxicam) capsules [prescribing information]. New York: Pfizer Labs; 2010.
43.
Kuehl GE, Bigler J, Potter JD, Lampe JW. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos. 2006;34:199–202.CrossRefPubMed
44.
Allegaert K, van Calsteren K, Hendrickx S, Kelchtermans J, Smits A, Kulo A, et al. Paracetamol and ketorolac pharmacokinetics and metabolism at delivery and during postpartum. Acta Anaesthesiol Belg. 2012;63:121–5.PubMed
45.
Gates BJ, Nguyen TT, Setter SM, Davies NM. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005;6:2117–40.CrossRefPubMed
46.
Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997;25:1072–80.PubMed
47.
Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005;29:590–8.CrossRefPubMed
48.
Zohydro ER (hydrocodone bitartrate) extended-release capsules [prescribing information]. San Diego: Zogenix, Inc.; 2014.
49.
Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57:287–97.PubMedCentralCrossRefPubMed
50.
Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004;32:930–6.PubMed
51.
Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010;70:78–87.PubMedCentralCrossRefPubMed
52.
Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig. 2011;31:143–53.CrossRefPubMed
53.
Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol. 2011;67:63–71.CrossRefPubMed
54.
Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001;29:1146–55.PubMed
55.
Codeine sulfate tablets [prescribing information]. Columbus: Roxane Laboratories, Inc.; 2013.
56.
Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 2011;88:959–71.PubMedCentralCrossRefPubMed
57.
Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363–74.CrossRefPubMed
58.
Kaletra (lopinavir/ritonavir) capsules [prescribing information]. North Chicago: AbbVie Inc.; 2013.
59.
Prozac (fluoxetine hydrochloride) pulvules for oral use [prescribing information]. Indianapolis: Lilly USA, LLC; 2014.
60.
Paxil (paroxetine hydrochloride) tablets and oral suspension [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2014.
61.
Savella (milnacipran HCl) tablets [prescribing information]. St. Louis: Forest Pharmaceuticals, Inc.; 2013.
62.
Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol. 2010;50:1180–7.CrossRefPubMed
63.
Luvox (fluvoxamine maleate) [prescribing information]. New South Wales: Abbot Australasia Pty Ltd; 2011.
64.
Remeron (mirtazapine) tablets [prescribing information]. Salt Lake City: Cephalon, Inc.; 2014.
65.
Wienkers LC, Allievi C, Hauer MJ, Wynalda MA. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999;27:1334–40.PubMed
66.
Ueda N, Yoshimura R, Umene-Nakano W, Ikenouchi-Sugita A, Hori H, Hayashi K, et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry. 2009;10:832–5.CrossRefPubMed
67.
Oleptro (trazodone hydrochloride) extended-release tablets [prescribing information]. Gaithersburg: Angelini Pharma Inc.; 2014.
68.
Effexor (venlafaxine hydrochloride) tablets [prescribing information]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2012.
69.
Polepally AR, Dutta S, Baykal T, Hu B, Podsadecki TJ, Awni WM, et al. Drug-drug interactions of omeprazole with the HCV direct acting antiviral (DAA) combination of ABT-450/r, ombitasvir and dasabuvir. Clin Pharm Ther. 2015;97(Suppl 1):S77–8.
70.
Dexilant (dexlansoprazole) delayed-release capsules for oral use [prescribing information]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2013.
71.
Nexium (esomeprazole magnesium) delayed-release capsules, for oral use [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals LP; 2014.
72.
Prevacid (lansoprazole) delayed-release capsules [prescribing information]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2012.
73.
Protonix (pantoprazole sodium) delayed-release tablets [prescribing information]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2013.
74.
Aciphex (rabeprazole sodium) delayed-release tablets, for oral use [prescribing information]. Eisai, Inc.; 2013.
75.
Tagamet (cimetidine) [product information]. Victoria: GlaxoSmithKline Australia Pty Ltd; 2008.
76.
Pepcid (famotidine) tablets [prescribing information]. Northbrook: Marathon Pharmaceuticals, LLC; 2014.
77.
Zantac (ranitidine hydrochloride) tablets [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2009.
78.
Midamor (amiloride HCl) tablets [prescribing information]. Whitehouse Station: Merck & Co, Inc.; 2002.
79.
Thalitone (chlorthalidone) tablets [prescribing information]. Bristol: King Pharmaceticals, Inc.; 2004.
80.
Microzide (hydrochlorothiazide) capsules [prescribing information]. Morristown: Watson Pharma, Inc.; 2011.
81.
Dyrenium (triamterene USP) capsules [prescribing information]. Oakville: WellSpring Pharmaceuticals Canada Corp; 2009.
82.
Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther. 1995;272:1076–81.PubMed
83.
84.
Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use [prescribing information]. Bridgewater: Sanofi-Aventis U.S. LLC; 2013.
85.
Arixtra (fondaparinux sodium) solution for subcutaneous injection [prescribing information]. Notre Dame de Bondeville: Aspen NDB; 2014.
86.
Verstuyft C, Delavenne X, Rousseau A, Robert A, Tod M, Diquet B, et al. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet. 2012;51:41–53.CrossRefPubMed
87.
Coumadin (warfain sodium) tablets, for oral use [prescribing information]. Princeton: Bristol-Myers Squibb Company; 2011.
88.
Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000;28:1284–90.PubMed
89.
Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. Eur J Clin Pharmacol. 2011;67:941–51.CrossRefPubMed
90.
Toon S, Heimark LD, Trager WF, O’Reilly RA. Metabolic fate of phenprocoumon in humans. J Pharm Sci. 1985;74:1037–40.CrossRefPubMed
91.
Eliquis (apixaban) tablets for oral use [prescribing information]. Princeton and New York: Bristol-Myers Sqibb Company and Pfizer, Inc.; 2014.
92.
Xarelto (rivaroxaban) tablets, for oral use [prescribing information]. Titusville: Janssen Pharmaceuticals, Inc.; 2014.
93.
Pradaxa (dabigatran etexilate mesylate) capsules [prescribing information]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.
94.
Plavix (clopidogrel bisulfate) tablets [prescribing information]. Bridgewater: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2013.
95.
Zhu Y, Zhou J. Identification of the significant involvement and mechanistic role of CYP3A4/5 in clopidogrel bioactivation. ACS Med Chem Lett. 2012;3:844–9.PubMedCentralCrossRefPubMed
96.
Effient (prasugrel) tablets [prescribing information]. Indianapolis: Daiichi Sankyo, Inc. and Lilly USA, LLC; 2013.
97.
Ancrenaz V, Deglon J, Samer C, Staub C, Dayer P, Daali Y, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112:132–7.PubMedCentralCrossRefPubMed
98.
Tenormin (atenolol) tablets [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals LP; 2012.
99.
Zebeta (bisoprolol fumurate) tablets [prescribing information]. Pamona: Duramed Pharmaceuticals, Inc.; 2011.
100.
Corgard (nadalol) tablets [prescribing information]. New York: Pfizer, Inc.; 2013.
101.
Betapace (sotalol HCl) [prescribing information]. Wayne: Bayer HealthCare Pharmaceuticals, Inc.; 2011.
102.
Zateyshchikov DA, Minushkina LO, Brovkin AN, Savel’eva EG, Zateyshchikova AA, Manchaeva BB, et al. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007;21:437–43.CrossRefPubMed
103.
Kudo S, Uchida M, Odomi M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol. 1997;52:479–85.CrossRefPubMed
104.
Lopressor (metoprolol tartrate) injection [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation; 2013.
105.
Bystolic (nebivolol) tablets [prescribing information]. St. Louis: Forest Pharmaceuticals, Inc.; 2011.
106.
Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Maenpaa J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007;35:1135–41.CrossRefPubMed
107.
Inderal (propranolol hydrochloride) tablets [prescribing information]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2011.
108.
Sectral (acebutolol hydrochloride) capsules [presribing information]. Bridgewater: Promius Pharma, LLC; 2011.
109.
Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos. 2009;37:1025–34.CrossRefPubMed
110.
Capoten (captopril) tablets [prescribing information]. Spring Valley: Par Pharmaceutical Companies, Inc.; 2012.
111.
Vasotec (enalapril) tablets [prescribing information]. Bridgewater: Valeant Pharmaceuticals North America LLC; 2012.
112.
Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988;25:9–15.PubMedCentralCrossRefPubMed
113.
Zestril (lisinopril) tablets, for oral use [prescribing information]. Wilmington,: AstraZeneca Pharmaceuticals LP; 2014.
114.
Aceon (perindopril erbumine) tablets [prescribing information]. Berkeley: XOMA (US) LLC; 2013.
115.
Accupril (quinapril hydrochloride) tablets [prescribing information]. New York: Parke-Davis; 2014.
116.
Altace (ramipril) capsules, oral [prescribing information]. New York: Pfizer, Inc.; 2014.
117.
Singhvi SM, Foley JE, Willard DA, Morrison RA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci. 1990;79:970–3.CrossRefPubMed
118.
Tian L, Liu H, Xie S, Jiang J, Han L, Huang Y, et al. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011;33:655–63.CrossRefPubMed
119.
Norvasc (amlodipine besylate) tablets for oral administration [prescribing information]. New York: Pfizer Labs; 2013.
120.
Procardia (nifedipine) capsules [prescribing information]. New York: Pfizer Labs; 2013.
121.
Nisoldipine extended-release tablets [prescribing information]. Mason: Prasco Laboratories; 2013.
122.
Soons PA, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50:394–403.CrossRefPubMed
123.
Verelan (verapamil hydrochloride) capsules [prescribing information]. Smyrna: Schwarz Pharma, LLC; 2011.
124.
Cardizem (diltiazem hydrochloride) direct compression tablets [prescribing information]. Bridgewater: BTA Pharmaceuticals, Inc.; 2010.
125.
Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000;28:125–30.PubMed
126.
Plendil (felodipine) extended-release tablets [prescribing information]. Wilmington: AstraZeneca LP; 2012.
127.
128.
Flynn CA, Hagenbuch BA, Reed GA. Losartan is a substrate of organic anion transporting polypeptide 2B1. FASEB J. 2010;24(758):2.
129.
Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res. 2012;29:411–26.PubMedCentralCrossRefPubMed
130.
Sun P, Wang C, Liu Q, Meng Q, Zhang A, Huo X, et al. OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human. Pharmacol Rep. 2014;66:311–9.CrossRefPubMed
131.
European Medicines Agency. Assessment report: Edarbi (azilsartan medoxomil). 2011.
132.
Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8:151–88.CrossRefPubMed
133.
Aldactone (spironolactone) tablets [prescribing information]. New York: G.D. Searle; 2013.
134.
Flecainide acetate [prescribing information]. Glasgow: Amneal Pharmaceuticals; 2013.
135.
Mexiletine hydrochloride [prescribing information]. Pulaski: AvKARE, Inc.; 2013.
136.
Cordarone (amiodarone HCl) tablets [prescribing information]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2014.
137.
Norpace (disopyramide phosphate) capsules [prescribing information]. New York: G. D. Searle LLC; 2006.
138.
Multaq (dronedarone) tablets [prescribing information]. Bridgewater: Sanofi-Aventis U.S. LLC; 2014.
139.
Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther. 2010;15:15S–8S.CrossRefPubMed
140.
Rythmol (propafenone hydrochloride) tablets for oral use [prescribing information]. Whippany: Halo Pharmaceutical, Inc.; 2013.
141.
Quinidine sulfate [prescribing information]. Corona: Watson Pharma, Inc.; 2012.
142.
Precose (acarbose) tablets [prescribing information]. Wayne: Bayer HealthCare Pharmaceuticals, Inc.; 2012.
143.
Riomet (metformin hydrochloride) oral solution [prescribing information]. Jacksonville: Ranbaxy Laboratories, Inc.; 2010.
144.
Januvia (sitagliptin) tablets [prescribing information]. Whitehouse Station: Merck & Co., Inc.; 2013.
145.
Galvus (vildagliptin) [precsribing information]. New South Wales: Novartis Pharmaceuticals Australia Pty Ltd; 2014.
146.
Actos (pioglitazone) tablets for oral use [prescribing information]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2013.
147.
Avandia (rosiglitazone maleate) tablets [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2014.
148.
Daonil (glibenclamide) tablets [prescribing information]. Auckland: Sanofi-Aventis New Zealand Limited; 2014.
149.
Amaryl (glimepiride) tablets [prescribing information]. Bridgewater: Sanofi-Aventis U.S. LLC; 2013.
150.
Tirkkonen T, Heikkila P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med. 2010;268:359–66.CrossRefPubMed
151.
Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286–96.CrossRefPubMed
152.
Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;43:84–91.CrossRefPubMed
153.
Onglyza (saxagliptin) tablets for oral use [prescribing information]. Princeton and Wilmington: Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP; 2013.
154.
Prandin (repaglinide) tablets [prescribing information]. Princeton: Novo Nordisk, Inc.; 2012.
155.
Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008;84:488–96.CrossRefPubMed
156.
Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005;78:388–99.CrossRefPubMed
157.
Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85:78–85.PubMedCentralCrossRefPubMed
158.
Lipitor (atorvastatin calcium) tablets [prescribing information]. New York: Parke-Davis; 2014.
159.
Baycol (cerivastatin sodium) tablets [prescribing information]. West Haven: Bayer Corporation Pharmaceutical Division; 2001.
160.
Niaspan (niacin extended-release) tablets [prescribing information]. North Chicago: Abbott Laboratories; 2013.
161.
Lovaza (omega-3-acid ethyl esters) capsules [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2014.
162.
Kynamro (mipomersen sodium) injection [prescribing information]. Cambridge: Genzyme Corporation; 2013.
163.
Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280–7.CrossRefPubMed
164.
Colestid (colestipol hydrochloride) oral suspension [prescribing information]. New York: Pharmacia & Upjohn Company; 2014.
165.
Welchol (colesevelam hydrochloride) [prescribing information]. Parsippany: Daiichi Sankyo, Inc.; 2014.
166.
Flomax (tamsulosin hydrochloride) capsules [prescribing information]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014.
167.
Cardura XL (doxazosin mesylate extended-release tablets) [prescribing information]. New York: Roerig; 2011.
168.
Uroxatral (alfuzosin HCl) extended-release tablets [prescribing information]. Cary: Covis Pharmaceuticals, Inc.; 2014.
169.
ProAir HFA (albuterol sulfate) inhalation aerosol [prescribing information]. Horsham: Teva Respiratory, LLC; 2012.
170.
Foradil Certihaler (formoterol fumarate) inhalation powder [prescribing information]. East Hanover: Novartis Pharmaceuticals Corp.; 2010.
171.
Serevent Diskus (salmeterol xinofoate) inhalation powder [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2014.
172.
Xanax (alprazolam) tablets [prescribing information]. New York: Pharmacia & Upjohn Co; 2011.
173.
Klonopin (clonazepam) tablets [prescribing information]. South San Francisco: Genentech USA, Inc.; 2013.
174.
Lunesta (eszopiclone) tablets for oral use [prescribing information]. Marlborough: Sunovion Pharmaceuticals, Inc.; 2014.
175.
Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005;35:455–65.CrossRefPubMed
176.
Mizuno K, Katoh M, Okumura H, Nakagawa N, Negishi T, Hashizume T, et al. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos. 2009;37:345–51.CrossRefPubMed
177.
Centrax tablets: Summary of product characteristics. Dublin: Pfizer Healthcare Ireland; 2013.
178.
Miura M, Ohkubo T. In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004;34:1001–11.CrossRefPubMed
179.
Sonata (zaleplon) capsules [prescribing information]. Bristol: King Pharmaceuticals, Inc.; 2013.
180.
Imovane (zopiclone) tablets [prescribing information]. New South Wales: Sanofi-Aventis Australia Pty Ltd; 2011.
181.
Valium (diazepam) tablets [prescribing information]. South San Francisco: Genentech USA, Inc.; 2013.
182.
Halcion (triazolam) tablets [prescribing information]. New York: Pharmacia & Upjohn Company; 2008.
183.
Depacon (valproate sodium) for intravenous injection [prescribing information]. North Chicago: AbbVie, Inc.; 2014.
184.
Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65:1441–9.CrossRefPubMed
185.
Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97–132.CrossRefPubMed
186.
Felbatol (felbamate) [prescribing information]. Somerset: Meda Pahrmaceuticals, Inc.; 2012.
187.
Neurontin (gabapentin) capsules for oral use [prescribing information]. New York: Parke-Davis; 2014.
188.
Topamax (topiramate) tablets for oral use [prescribing information]. Titusville: Janssen Pharmaceuticals, Inc.; 2014.
189.
Sabril (vigabatrin) tablets for oral use [prescribing information]. Deerfield: Lundbeck; 2014.
190.
Keppra (levetiracetam) tablets for oral use [prescribing information]. Smyrna: UCB, Inc.; 2014.
191.
Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009;37:229–36.PubMedCentralCrossRefPubMed
192.
Gabitril (tiagabine hydrochloride) tablets [prescribing information]. Frazer: Cephalon, Inc.; 2010.
193.
Zonegran (zonisamide) capsules [prescribing information]. Woodcliff Lake: Eisai, Inc.; 2012.
194.
195.
Moore CD, Roberts JK, Orton CR, Murai T, Fidler TP, Reilly CA, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013;41:379–89.PubMedCentralCrossRefPubMed
196.
Solu-Medrol (methylprednisolon sodium succinate) for injection [prescribing information]. New York: Pharmacia & Upjohn Co.; 2014.
197.
Asmanex HFA (mometasone furoate) inhalation aerosol [prescribing information]. Whitehouse Station: Merck & Co., Inc.; 2014.
198.
199.
Schwarze-Zander C, Klingmuller D, Klumper J, Strassburg CP, Rockstroh JK. Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature. Infection. 2013;41:1183–7.CrossRefPubMed
200.
Norvir (ritonavir) tablets for oral use [prescribing information]. North Chicago: AbbVie, Inc.; 2013.
201.
Boyd SD, Hadigan C, McManus M, Chairez C, Nieman LK, Pau AK, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr. 2013;63:355–61.PubMedCentralCrossRefPubMed
202.
Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–50.CrossRefPubMed
203.
Amoxil (amoxicillin) [prescribing information]. Bridgewater: Dr. Reddy’s Laboratories; 2011.
204.
Zithromax (azithromycin) tablets [prescribing information]. New York: Pfizer Labs; 2007.
205.
Keflex (cephalexin) capsules [prescribing information]. Germantown: Advancis Pharmaceutical Corporation; 2006.
206.
Cipro (ciprofloxacin hydrochloride) tablets [prescribing information]. Wayne: Bayer HealthCare Pharmaceuticals, Inc.; 2013.
207.
Biaxin Filmtab (clarithromycin) tablets [prescribing information]. North Chicago: AbbVie, Inc.; 2014.
208.
Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol. 2000;40:1522–7.PubMed
209.
Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther. 1998;64:355–62.CrossRefPubMed
210.
Fucidin (fusidic acid) suspension [product information]. Victoria: CSL Biotherapies; 2012.
211.
Itraconazole (prescribing information). Research Triangle Park: Stiefel Laboratories, Inc.; 2010.
212.
Noxafil (posaconazole) oral suspension [prescribing information]. Whitehouse Station: Schering Corporation; 2012.
213.
Vfend (voriconazole) tablets [prescribing information]. New York: Pfizer, Inc.; 2003.
214.
Cancidas (caspofungin acetate) for injection [prescribing information]. Whitehouse Station: Merck Sharp & Dohme Corp.; 2014.
215.
Mycamine (micafungin sodium) for injection [prescribing information]. Northbrook: Astellas Pharma US, Inc.; 2013.
216.
Eraxis (anidulafungin) for injection [prescribing information]. New York: Roerig; 2012.
217.
Revatio (sildenafil) tablets [prescribing information]. New York: Pfizer Labs; 2014.
218.
Cialis (tadalafil) tablets [prescribing information]. Indianapolis: Lilly USA, LLC; 2014.
219.
Levitra (vardenafil hydrochloride) tablets [prescribing information]. Research Triangle Park: GlaxoSmithKline; 2014.
220.
Stendra (avanafil) tablets [prescribing information]. Mountain View: Vivus, Inc.; 2014.
221.
Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117:10–3.CrossRefPubMed
222.
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004;32:1201–8.CrossRefPubMed
223.
Lanzafame M, Trevenzoli M, Faggian F, Marcati P, Gatti F, Carolo G, et al. Interaction between levothyroxine and indinavir in a patient with HIV infection. Infection. 2002;30:54–5.CrossRefPubMed
224.
Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15(5):1313–22. doi:10.​1111/​ajt.​13111.CrossRefPubMed
225.
Menon R, Badri P, Das U, Wang T, Polepally A, Khatri A, et al. Drug-drug interactions with direct acting antiviral combination therapy of ABT-450/r, ombitasvir and dasabuvir. In: AASLD/EASL Special Conference on Hepatitis C. New York; 2014.
226.
Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, et al. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies. J Hepatol. 2015;62:S644.CrossRef
227.
Polepally AR, Badri P, Coakley EP, Parikh A, Rodrigues L, Jr., DaSilva-Tillmann BA, et al. Effect of comedications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC; 2015.
Metadata
Title
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
Authors
Prajakta S. Badri
Jennifer R. King
Akshanth R. Polepally
Barbara H. McGovern
Sandeep Dutta
Rajeev M. Menon
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 3/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0317-8

Other articles of this Issue 3/2016

Clinical Pharmacokinetics 3/2016 Go to the issue

Review Article

Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

Original Research Article

Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study

Erratum

Erratum to: Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer

Review Article

A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans

Original Research Article

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy

Original Research Article

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies